Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Antibe Therapeutics Provides an Update on Its Data Review and Corporate Strategy

Business Wire March 11, 2015

Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation

Business Wire February 27, 2015

Antibe Therapeutics Announces No Material Change

Business Wire February 4, 2015

Microcap Report: Orbite Aluminae (T.ORT) active on prospectus filing news

Stockhouse Editorial January 16, 2015

Antibe (V.ATE) halts Phase I clinical trials amid safety concerns, shares dump 80%

Stockhouse Editorial January 16, 2015

Antibe Therapeutics Suspends Its Phase I Clinical Trial Due to Safety Concerns

Business Wire January 16, 2015

Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to Its Clinical Advisory Board

Business Wire December 18, 2014

Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant

Business Wire December 16, 2014

Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results

Business Wire November 28, 2014

Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352

Business Wire November 25, 2014

Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program

Business Wire October 6, 2014

Antibe Therapeutics Reports on Results of AGM Voting

Business Wire October 3, 2014

OTC Markets Group Welcomes Antibe Therapeutics to OTCQX®

PR Newswire September 15, 2014

Antibe Therapeutics' Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease

Business Wire September 5, 2014

Antibe Therapeutics Reports Q1 2015 Interim Financial and Operating Results

Business Wire August 28, 2014

Antibe Therapeutics Reports Year-End Financial and Operating Results

Business Wire July 28, 2014

Antibe Therapeutics Announces the Formation of Its Clinical Advisory Board

Business Wire July 17, 2014

Antibe Therapeutics Announces First Human Dose of ATB-346 in Phase I Clinical Trial

Business Wire June 26, 2014

Antibe Therapeutics Receives Approval from Health Canada to Begin Human Clinical Testing

Business Wire June 19, 2014

Antibe Therapeutics Announces Submission of Clinical Trial Application to Health Canada For ATB-346

Business Wire May 21, 2014